Inhibikase grants director 310,000 stock options

Inhibikase Therapeutics, Inc. (IKT) director Scott M. Wasserman was granted stock options covering 310,000 shares of common stock on October 19, 2026, at an exercise price of $1.645 per share.

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. (IKT) director Scott M. Wasserman was granted stock options covering 310,000 shares of common stock on October 19, 2026, at an exercise price of $1.645 per share. The options vest and become exercisable in equal annual installments over three years beginning October 19, 2026, subject to continued service through each vesting date.

Insider Trade Summary

Grant/Award: 310,000 shares

Grant/Award 1 txn

Insider Wasserman Scott M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	310,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 310,000 contracts (Direct)

Footnotes (1)

1. F1. The options will vest and become exercisable in equal annual installments over three years commencing from October 19, 2026, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Option award: 310,000 options covering common shares Exercise price: $1.645 per share Vesting period: Three years +1 more

4 metrics

Option award 310,000 options covering common shares Granted October 19, 2026

Exercise price $1.645 per share For the granted options

Vesting period Three years Equal annual installments beginning October 19, 2026, subject to continued service through each vesting date

Option expiration October 19, 2036 Expiration date of the granted options

Key Terms

Stock Option (Right to Buy), exercise price, exercisable

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"exercise price of $1.645"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

exercisable financial

"become exercisable in equal annual installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did IKT director Scott M. Wasserman receive?

Scott M. Wasserman was granted options covering 310,000 shares of Inhibikase Therapeutics common stock. The options have an exercise price of $1.645 per share and expire October 19, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 04:13 PM EDT Accepted by SEC EDGAR 10/21/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wasserman Scott M.

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.645	10/19/2026		A		310,000		(1)	10/19/2036	Common Stock	310,000	$0	310,000	D

Explanation of Responses:

1. The options will vest and become exercisable in equal annual installments over three years commencing from October 19, 2026, subject to the Reporting Person's continued service through each such vesting date.

	/s/ David McIntyre, attorney-in-fact	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)